Document:

Exhibit 4.10

                             SUBSCRIPTION AGREEMENT
                                      FOR
                     MEDISCIENCE TECHNOLOGY CORP.(OTC-MDSC)

If you are interested in purchasing shares ("Shares") of the common stock (the
Common Stock") of Mediscience Technology Corp. (the "Company"), you must:

      a)    complete this Subscription Agreement (the "Agreement");

      b)    provide a check or money order (unless a wire transfer is being
            sent) made payable to "Mediscience Technology Corp. for deposit only
            to / Solomon Smith Barney Account No. 715-17097"

      c)    deliver both the Agreement and payment to:

                  Agent: Peter Katevatis Esquire
                Address: 2318 Perot Street
                         Philadelphia, Penna 19130

The Company may accept or reject any subscription you tender, in whole or in
part. This means that the Company may allocate to you a smaller number of Shares
than you subscribed to purchase. If accepted by the Company, then this Agreement
will constitute your subscription for ____share/s of Mediscience non-interest
bearing convertible preferred, with each individual dollar investment to be no
less than $25,000 for each of a total of forty (60) but not less than twenty
(20) MTC CP. Shares. Each non-interest bearing convertible preferred share on
conversion equal to (100,000 shares of unregistered MTC common valued at $.25
cents per share).

NOTE: The execution and delivery of, and the performance by the Company of its
obligations under, the subscription agreements and PPM documents, including the
offer, issuance, sale and delivery of the non-interest bearing convertible
preferred, are within the Company's corporate power, (The issuer has 50,000
Preferred shares authorized with none outstanding as of this date except for the
sixty to be issued as a result of this transaction), have been duly authorized
by all necessary corporate action, do not require approval of any government
body, agency or official and do not and will not, conflict with, violate or
contravene, or constitute a default under, any applicable law or regulation, but
will require corporate action as follows:

Assuming a total of $1.5 Million dollars invested, the Company on conversion of
all sixty MTC CP shares will be obligated to issue a total of six million shares
which will require the Company's best efforts, without guarantee of shareholder
approval, in conducting a timely shareholder meeting and securing the approval
for an appropriate increase in the NJ Article/Certificate of Incorporation
authorized Common shares increase from 40 million to 200 million. Common shares
outstanding of the Company's most recent 10-Q see EDGAR SEC filings dated
Oct 14, 2003 was: 39,372,753

                                       1
<PAGE>

                                     NOTICE

THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK (SEE RISK FACTORS) AND IS
SUITABLE ONLY FOR THOSE PERSONS WHO CAN MEET MINIMUM INVESTOR SUITABILITY
STANDARDS (SEE TERMS OF OFFERING). THE UNITS ARE NOT READILY TRANSFERABLE AND
SHOULD ONLY BE PURCHASED FOR LONG-TERM INVESTMENT. ACCORDINGLY, EACH INVESTOR
MUST DEMONSTRATE THAT HE HAS THE ABILITY TO EVALUATE THIS OFFERING.

PROSPECTIVE INVESTORS ARE NOT TO CONSTRUE THE CONTENTS OF THIS MEMORANDUM AS
LEGAL OR BUSINESS ADVICE. EACH INVESTOR SHOULD CONSULT HIS PERSONAL COUNSEL,
ACCOUNTANT, AND OTHER ADVISORS AS TO LEGAL, ECONOMIC AND RELATED, MATTERS
CONCERNING THE INVESTMENT DESCRIBED HEREIN AND ITS SUITABILITY FOR HIM/HER

THE COMPANY SHALL MAKE AVAILABLE TO EACH INVESTOR, OR HIS AGENT, DURING THIS
OFFERING AND PRIOR TO THE SALE OF ANY UNITS, THE OPPORTUNITY TO ASK QUESTIONS OF
AND RECEIVE ANSWERS FROM THE COMPANY CONCERNING ANY ASPECT OF THE INVESTMENT AND
TO OBTAIN ANY ADDITIONAL INFORMATION NECESSARY TO VERIFY THE ACCURACY OF THE
INFORMATION CONTAINED IN THESE MEMORANDUM, TO THE EXTENT THE COMPANY POSSESS
SUCH INFORMATION OR CAN ACQUIRE IT WITHOUT UNREASONABLE EFFORT OR EXPENSE.

SALES OF THESE UNITS CAN BE CONSUMMATED ONLY BY THE COMPANY'S ACCEPTANCE OF
OFFERS BY PROSPECTIVE INVESTORS. THIS MEMORANDUM CONSTITUTES SUCH A SOLICITATION
FOR AN OFFER ONLY IF THE PROSPECTIVE INVESTOR'S NAME APPREARS ON THE COVER PAGE

THE UNITS ARE OFFERED SUBJECT TO PRIOR SALE, WHEN, AS, AND IF DELIVERED TO AND
ACCEPTED BY THE COMPANY AND SUBJECT TO APPROVAL OF CERTAIN LEGAL MATTERES BY
COUNSEL AND CERTAIN OTHER CONDITIONS. THE COMPANY RESERVES THE RIGHT TO REJECT
ANY SUBSCRIPTIONS IN WHOLE OR PART.

SALES BY THE COMPANY OF THE UNITS ARE MADE IN RELIANCE ON EXEMPTIONS FROM
REGISTRATION CONTAINED IN THE SECURITIES ACT OF 1933, AS AMENDED, THE RULES AND
REGULATIONS PROMULGATED THEREUNDER AND APPLICABLE STATE SECURITIES LAWS. THE
UNITS HAVE NOT BEEN REGISTERED UNDER THE SAID ACT OR THE SECURITIES LAWS OF ANY
STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF BY AN INVESTOR UNLESS SO REGISTERED, OR UNLESS IN THE OPINION OF
COUNSEL FOR THE COMPANY SUCH REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR ANY
SAID LAW. ACCORDINGLY THE TRANSFERABILITY OF THE UNITS IS SEVERELY LIMITED. NO
MARKET MAY DEVELOP FOR THE UNITS, UNITS NEEDING LIQUIDITY SHOULD NOT BE
PURCHASED BECAUSE SUCH INVESTORS MAY BE UNABLE TO LIQUIDATE THEIR INVESTMENT
QUICKLY OR ON ACCEPTABLE TERMS, IF AT ALL, IF THEY DESIRE TO DO SO (SEE RISK
FACTORS)

                        NOTICE TO CONNECTICUT RESIDENTS

THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE BANKING
COMMISSIONER OF THE STATE OF CONNECTICUT NOR HAS THE COMMISSIONER PASSED UPON
THE ACCURACY OR ADEQUACY OF THIS OFFERING. ANY REPRESENTATION TO THE CONTRARY IS
UNLAWFUL

THE UNITS HAVE NOT BEEN REGISTERED UNDER SECTION 36-485 OF THE CONNECTICUT
UNIFORM SECURITIES ACT BUT WILL BE SOLD IN RELIANCE ON THE EXEMPTION OF SUCH
REGISTRATION SET FORTH IN SECTIONS 36-490(b)(9)(A) OF SAID ACT AND REGULATIONS
PROMULGATED THEREUNDER. THE SAID SHARES CANNOT BE RESOLD WITHOUT REGISTRATION
UNDER SECTION 36-485 OF SAID ACT OR AN EXCEPTION FROM REGISTRATION PURSUANT TO
SECTION 36-490 OF SAID ACT.

                          NOTICE TO FLORIDA RESIDENTS

THE SECURITIES REFERRED TO IN THIS MEMORANDUM WILL BE SOLD TO, AND ACQUIRED BY,

                                       2
<PAGE>

THE HOLDER IN A TRANSACTION EXEMPT UNDER SECTION 517.061 OF THE FLORIDA
SECURITIES ACT. THE SECURITIES HAVE NOT BEEN REGISTERED UNDER SUCH ACT IN THE
STATE OF FLORIDA AND, UNLESS THE SECURITIES ARE REGISTERED, THEY MAY NOT BE
OFFERED FOR SALE OR RESOLD UNLESS THEY ARE REGISTERED OR UNLESS AN EXEMPTION
FROM REGISTRATION IS AVAILABLE. IN ADDITION FLORIDA RESIDENTS SHALL HAVE THE
PRIVILEDGE OF VOIDING THE PURCHASE WITHIN 3 DAYS OF THEIR TENDERING OF ANY
CONSIDERATION FOR THEIR PURCHASE OR THEIR RECEIVING NOTICE OF SUCH PRIVILEDGE
WHICHEVER OCCURS LATER TO ACCOMPLISH THE FOREGOING, THE SUBSCRIBER NEED ONLY
SEND A LETTER OR TELEGRAM TO THE COMPANY INDICATING HIS INTENTION TO WITHDRAW.
THE LETTER OR TELEGRAM SHOULD BE SENT AND POSTMARKED PRIOR TO THE END OF THE
AFOREMENTIONED THIRD DAY. IF THE SUBSCRIBER SENDS A LETTER IT IS PRUDENT TO SEND
IT BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO ENSURE THAT IT IS RECEIVED
AND ALSO TO EVIDENCE THE TIME WHEN IT WAS MAILED.

                         NOTICE TO NEW JERSEY RESIDENTS

THIS CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM HAS NOT BEEN FILED WITH OR
REVIEWED BY THE NEW JERSEY BUREAU OF SECURITIES OR THE DEPARTMENT OF LAW AND
PUBLIC SAFETY OF THE STATE OF NEW JERSEY PRIOR TO ITS ISSUANCE AND USE. NEITHER
THE ATTORNEY GENERAL, OR THE STATE OF NEW JERSEY NOR THE BUREAU OF SECURITIES
HAS PASSED ON OR ENDORSED THE MERITS OF THIS MEMORANDUM, OR THE PRIVATE OFFERING
CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.

                          NOTICE TO NEW YORK RESIDENTS

THIS CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM HAS NOT BEEN FILED WITH OR
REVIEWED BY THE ATTORNEY GENERAL OF THE STATE OF NEW YORK PRIOR TO ITS
ISSUANCE AND USE. THE ATTORNEY GENERAL, OF THE STATE OF NEW YORK HAS PASSED ON
OR ENDORSED THE MERITS OF THIS MEMORANDUM, OR THE PRIVATE OFFERING CONTAINED
HEREIN. ANY REPRESENTATIONS TO THE CONTRARY ARE UNLAWFUL.

The minimum subscription is $25,000 for one share of Mediscience non-interest
bearing preferred. You should pay by check, money order or wire transfer payable
to "Mediscience Technology Corp. for deposit only to /Solomon Smith Barney
Account No 715-17097 Corporate Account." If the Company rejects your
subscription in whole, the Company will return this Agreement and your payment.

If the Company accepts your subscription in whole or in part, a copy of this
Agreement will be returned to you as your receipt. This will confirm your
subscription and indicate how much of your subscription the Company has
accepted. All proceeds of the Offering will be held in an a Mediscience
Corporate Account at Solomon Smith Barney Account No. 715-17097

When the Company sells its Minimum Subscription, the funds held in the Solomon
Smith Barney Corporate Account will be disbursed to the Company and non-interest
bearing convertible preferred share certificates will be issued through MTC's
transfer agent Registrar and Transfer Co. One Mediscience Technology Corp.
non-interest bearing convertible preferred share certificate for each $25,000
dollars invested.

If the Company accepts only part of your subscription, the Company will return
the unused portion of your payment to you with interest, if any. If the Minimum
Subscription is not sold or waived by Mediscience prior to the Termination Date
of the Offering, then all deposits will be returned to subscribers with interest
earned, if any.

                                       3
<PAGE>

You irrevocably submit this Agreement for the purchase of _____ Mediscience
Technology non-interest bearing convertible preferred stock certificates at
$25,000 per Share. With this Agreement, you also submit payment in the amount of
$________ __ ($25,000 per Share) for the Share/s subscribed.

In connection with this investment, you represent to the Company that:

a.    Before submitting payment for the Shares, you received the Company's
      Disclosure Document (including SEC 10-K 2003), and have reviewed all
      Mediscience Technology 10-QSB filings to date January 13, 2004

b.    You are a resident of ______________,____________. (State) (Country)

      (If the Offering has not been qualified or registered in that jurisdiction
      or is not exempt from the registration requirements in that jurisdiction,
      your subscription will not be accepted.)

c.    The Social Security number or taxpayer identification number that you
      included in this Agreement is your true, correct and complete
      identification number.

d.    You are not subject to backup withholding of interest or dividends by the
      Internal Revenue Service.

The Shares should be registered as follows:

      Name: _________________________________________

As (check one):

___ Individual                       ___ Tenants-in-Common
___ Partnership                      ___ Joint Tenants
___ Corporation                      ___ Trust
___ Minor with adult custodian       ___ Other
    Under the Uniform Gift
    to Minors Act

Individual(s) Registration:

______________________________________      ____________________________________
Investor No. 1 (print name above)           Investor No. 2 (print name above)

______________________________________      ____________________________________
Street (residence address)                  Street (residence address)

                                       4
<PAGE>

______________________________________      ____________________________________
City        State           Zip             City          State         Zip

______________________________________      ____________________________________
Home Phone                                  Home Phone

______________________________________      ____________________________________
Social Security Number                      Social Security Number

______________________________________      ____________________________________
Date of Birth                               Date of Birth

______________________________________      ____________________________________
Signature                                   Signature

______________________________________      ____________________________________
Date                                        Date

Entity (Not Individual) Registration:

On behalf of the entity named below, you represent that you have full power and
authority to execute this Agreement. You also represent that investment in the
Company is not prohibited by any of the governing documents of the entity.

Name of Entity

By: __________________________________      ____________________________________
    Signature of trustee, partner or        Date
    authorized officer

Title:________________________________

______________________________________      ____________________________________
Street Address                              Taxpayer ID Number

______________________________________      ____________________________________
City           State          Zip           Telephone

                                       5
<PAGE>

ACCEPTED BY MEDISCIENCE TECHNOLOGY CORP. FOR ______ SHARE/S OF MEDISCIENCE
TECHNOLOGY CORP. non-interest bearing convertible preferred, with each
individual dollar investment to be no less than $25,000 for each of a total of
forty (60) but not less than twenty (20) MTC non-interest bearing convertible
preferred shares. Each non-interest bearing convertible preferred share equal to
(100,000 shares of unregistered MTC common on conversion valued at $.25 cents
per share).

By: __________________________________          Date:___________________________

Title: Chairman/CEO
Mediscience Technology Corp.
Cherry Hill NJ

                                       6
<PAGE>

                                  THE OFFERING

Amount of Investment:                   Up to an aggregate of $1,500,000
                                        offered to outside Investors.

Type of Security:                       Callable, non-interest bearing
                                        Convertible Preferred shares, with
                                        investment to be no less than $25,000
                                        for each share convertible at the
                                        discretion of the company into 100,000
                                        shares of Mediscience common. ("The
                                        "Offering").

Number of Units Offered:                Up to 60 Units. The Units are being
                                        offered on a "best efforts - all or
                                        none" as to 20 Units and a "best
                                        efforts" basis as to the remaining 20
                                        Units.

Price Per Unit:                         $25,000 ("Purchase Price").

Minimum Proceeds:                       $500,000.

Valuation of the Company:               Pre-Money $12,000,000 @ $.30 cents per
                                        share
                                        Post-Money $15,000,000+ assuming $.30
                                        cents per share

Capitalization of the                   o     Mediscience Technology Corp.
Company:                                      ("MDSC) currently owns 100% of all
                                              Preferred shares, of the Company.
                                              (50,000 authorized 10-K 2003)

                                        o     After proposed financing MDSC
                                              would retain 49,940 while
                                              investors will own 60, if all 60
                                              Units are sold.

Rights, Preferences, Privileges         Description: MTC management can at any
and Restrictions:                       time and for any reason immediately
                                        after the next MTC shareholder meeting
                                        without notice to the investor convert
                                        all 60 MTC CP shares issued into a
                                        total of SIX Million MTC common or
                                        100,000 shares on each of the 60 MTC
                                        CP shares. On such event MTC will
                                        deliver the MTC common to each
                                        investor through MTC agent Registrar
                                        and Transfer Co. canceling the
                                        converted MTC CP as a matter of
                                        record.

                                        (Callable non-interest bearing
                                        Convertible Preferred shares, with
                                        investment to be no less than $25,000
                                        for each share convertible at the SOLE
                                        discretion of the company into 100,000
                                        shares of Mediscience common. ("The
                                        "Offering")

                                        (1)   Liquidation Preference and
                                              Dissolution Rights: In the event
                                              of any liquidation of the Company,
                                              the Unit holders shall be entitled
                                              to receive, as a preference to the
                                              holders of MTC Common Shares, an
                                              amount ("Liquidation Preference")
                                              equal to the Original Purchase
                                              Price only. The close of a
                                              transaction or series of
                                              transactions in which more than
                                              80% of the voting power of the
                                              Company is disposed of to a single
                                              person or group of affiliated
                                              persons, or the consolidation or
                                              merger of the Company with or into
                                              any other corporation or
                                              corporations, or the sale of all
                                              or substantially all of its assets
                                              shall be deemed to be a
                                              liquidation.

                                       I
<PAGE>

Transfer Restrictions: none             The Series A are transferable.

Right of First Offer:                   In the event MTC offers another PPM
                                        Unit, each investor of this PPM shall
                                        have the opportunity to purchase a pro
                                        rata percentage of Units in the new
                                        offering, based on the holder's
                                        percentage ownership interest in the
                                        Company. This right is not transferable.

Use of Proceeds:                        The proceeds from the sale of the Series
                                        A Units will be used, at the discretion
                                        of the Company's management, to fund the
                                        following activities:

<TABLE>
                                        --------------------------------------------------------
<S>                                                                                 <C>
                                        Recruit/Retain Management and Staff         $  250,000
                                        --------------------------------------------------------
                                        Clinical Development of PhotonX(TM)
                                        {Cervical)                                  $  200,000
                                        --------------------------------------------------------
                                        PhotonX(TM) (Cervical, etc.) Prototypes     $  200,000
                                        --------------------------------------------------------
                                        Regulatory, Medical and Scientific          $  200,000
                                        Affairs
                                        --------------------------------------------------------
                                        Market Research: The Adoption Equation      $  100,000
                                        --------------------------------------------------------
                                        Other Working Capital & Closing Fees        $  550,000
                                        --------------------------------------------------------
                                        TOTAL                                       $1,500,000
                                        --------------------------------------------------------
</TABLE>

Risk Factors:                       The Units are speculative and involve a
                                    high degree of risk. Only those
                                    investors who can bear the risk of loss
                                    of their entire investment should
                                    invest. Investment Risk Factors are
                                    profiled in the Confidential Investment
                                    Summary and/or Private Placement
                                    Memorandum distributed to each Investor.

Investor Suitability:               The Units are suitable for those
                                    investors whose business and investment
                                    experience, either alone or together
                                    with an experienced advisor, makes them
                                    capable of evaluating the merits and
                                    risks of a potential investment in the
                                    Company and who can afford the loss of
                                    their entire investment and have no need
                                    for liquidity in their investment.

Expenses:                           The Company and the Investors shall each
                                    be responsible for their own expenses in
                                    connection with this Unit financing.

Closing:                            An initial closing shall be held
                                    following receipt into escrow of the
                                    Minimum Proceeds and additional closings
                                    shall be held thereafter during the
                                    offering period as subscriptions for at
                                    least $100,000 are received and cleared
                                    in the escrow account. The Final Closing
                                    is expected to occur no later than
                                    January 15, 2003, unless extended at the
                                    discretion of Mediscience Technology
                                    ("Placement Agent") in 30 day
                                    increments. The closing of the
                                    transaction, if all conditions are met,
                                    is expected to occur on or before
                                    February 1st, 2004 (the "Closing
                                    Date").

                                    Capital contributions accepted prior to
                                    closing will be deposited in an
                                    interest-bearing escrow account at
                                    Solomon Smith Barney administered by
                                    Peter Katevatis Esq. Counsel to the
                                    Company.

Conditions of Closing:              The closing for the purchase and sale of
                                    the Units will be conditioned upon
                                    execution of final, binding agreements
                                    in

<PAGE>

                                   compliance with applicable securities
                                   laws.

Investment Banker to the           THM Group, LLC 161 North Franklin Turnpike,
Company:                           Suite 204
                                   Ramsey, New Jersey 07446 USA
                                   Phone: (201) 818-0050 Fax: (201) 825-3178
                                   Email: mengelhart@thmgroupllc.com
                                   Attn:  Michael W. Engelhart

Shelf Registration                 It is understood and agreed that MTC will
                                   file an SEC resale shelf registration S-3
                                   for no less than four million shares
                                   within a period of 6 months or sooner.

Associate Counsel to the           Warshaw Burstein Cohen Schlesinger &
Company:                           Kuh, LLP
                                   555 Fifth Avenue, 11th Floor
                                   Attn Peter Hirshfield Esq.
                                   New York, New York 10017 USA
                                   Phone: (212) 984-7836
                                   Fax:   (646) 349-1665
                                   Email: phirshfield@wbcsk.com

                           Forward-Looking Statements

All statements other than statements of historical fact included in this
Memorandum, including, without limitation, statements under "Risk Factors" and
"Business" regarding our anticipated financial position, business strategy and
plans and objectives of our management for future operations, are
forward-looking statements. When used in this Memorandum, words such as
"anticipate," "believe," "estimate," "plans," "expect," "intend" and similar
expressions, as they relate to Mediscience Technology Corp. or the management of
the corporate organization, identify forward-looking statements. Any
forward-looking statements are based on the beliefs of our management as well as
assumptions made by and information currently available to our management.
Actual results could differ materially from those contemplated by the forward-
looking statements as a result of certain factors, such as those disclosed under
"Risk Factors," including, but not limited to, our plans to develop our
PhotonX(TM) products, engage in pre-clinical testing and clinical trials, seek
FDA approval, develop manufacturing/marketing alliances, pricing pressures,
finance and administrative functions, competitive factors and, changes in legal
and regulatory requirements, general economic conditions and our planned use of
the proceeds of this Offering. Any forward-looking statements reflect our
current views with respect to future events and are subject to these and other
risks, uncertainties and assumptions relating to our operations, results of
operations, growth strategy and liquidity. All subsequent written and oral
forward-looking statements attributable to us or persons acting on our behalf
are expressly qualified in their entirety by this paragraph.

                                       9
<PAGE>

                          MEDISCIENCE TECHNOLOGY CORP.

                  ACCREDITED INVESTOR SUITABILITY QUESTIONNAIRE

THIS QUESTIONNAIRE IS TO BE COMPLETED AND DELIVERED TO MEDISCIENCE TECHNOLOGY
CORP. WITH THE DELIVERY OF A SUBSCRIPTION AGREEMENT

INSTRUCTIONS:

If the answer to any questions is "None" or "Not Applicable", please state so.

Your answers will, at all times, be kept strictly confidential; however, each
organization which agrees to purchase any Units of the Company and agrees that
the Company may present this Questionnaire to such persons as they deem
appropriate in order to insure themselves that the offer and sale of Units of
the Company (sometimes referred to as the "CP") to you will not result in
violation of the exemption from registration under the Securities Act of 1933,
as amended, and the securities laws of certain states, which is being relied
upon by the Company in connection with the sale.

                         (Print or type your responses)

1.    Name: ____________________________________________________________________

      Date of birth or year of organization: ___________________________________

2.    Home address or, of other than an individual, principal office address:___

                                       10
<PAGE>

         _______________________________________________________________________

         _______________________________________________________________________

3.    I am subscribing for __________ Units.

4.*   Employer:_________________________________________________________________

      Nature of Business:_______________________________________________________

      Position:_________________________________________________________________

      Nature of duties:_________________________________________________________

      Business address:_________________________________________________________

      Business telephone number:________________________________________________

5.    In the case of any individual investor, I am an accredited investor (as
      defined in Rule 501 of Regulation D) because I certify that (check each
      appropriate description):

* This question is to be answered if the investor is an individual.

      (a)  _____  I am a natural person whose individual net worth, or joint net
                  worth with my spouse, exceeds $1,000,000.(1)

      (b)  _____  I am a natural person who had individual income exceeding
                  $200,000 in 2001 and 2002 and I have a reasonable expectation
                  of reaching the same income level in 2003.(2)

      (c)  _____  I am a natural person who had joint income with my spouse
                  exceeding $300,000 in 2001 and 2002 and I have a reasonable
                  expectation of reaching the same income level in 2003, as
                  defined above.

      (d)  _____  I am a director or executive officer of the Company.
                  (Executive officer means the president, any vice president in
                  charge of a principal business unit, division or function,
                  such as sales, administration or finance, or any other person
                  who persons similar policy-making functions for the Company.)
----------

      (1)   For purposes of this item, "individual net worth" means the excess
            of total assets at fair market value, including home and personal
            property (and including property owned by a spouse), over total
            liabilities.

      (2)   For purposes of this questionnaire, "individual income" means
            individual annual adjusted gross income, as reported for Federal
            income tax purposes, plus (i) the amount of any tax-exempt interest
            income received, (ii) the amount of losses claimed as a limited
            partner in a limited partnership, (iii) any deduction claimed for
            depletion, (iv) amounts contributed to an IRA or Keogh retirement
            plan, (v) alimony paid and (vi) any amount by which income from
            long-term capital gains has been reduced in arriving at adjusted
            gross income pursuant to the provisions of Section 1202 of the
            Internal Revenue Code of 1986, as amended.

                                      2-B
<PAGE>

6.    In the case of any partnership, corporation, trust and other entity
      investor, the undersigned certifies (check one):

      (a)(3)______    The investor certifies that each equity owner of the
                      investor is an accredited investor and that each such
                      equity owner has completed an Accredited Investor
                      Suitability Questionnaire certifying that he, she or it
                      meets one of the following five conditions of
                      accreditation:

            (i)       The equity owner of the investor is a natural person who
                      had an individual income (exclusive of any income
                      attributable to his or her spouse) in excess of $200,000
                      (or joint income with that of his spouse in excess of
                      $300,000) in each of 2001 and 2002 and reasonably and
                      fully expects to have an individual income in excess of
                      $200,000 (or joint income with that of his spouse in
                      excess of $300,000) in 2003. "Individual income" is
                      defined in item 5(b) above;

            (ii)      The equity owner is a natural person who has an
                      "individual net worth" (or who, with his or her spouse has
                      a combined individual net worth) in excess of $1,000,000.
                      "Individual net worth" is defined in item 5(a) above;

            (iii)     The equity owner is, or is a director or executive officer
                      of, the Company;

            (iv)      The equity owner is either (i) a bank as defined in
                      Section 3(a)(2) of the Act whether acting in its
                      individual or fiduciary capacity; (ii) an insurance
                      company as defined in Section 2(13) of the Act; (iii) an
                      investment company registered under the Investment Company
                      Act of 1940 or a business development company as defined
                      in Section 2(a)(48) of that Act; (iv) a Small Business
                      Investment Company licensed by the U.S. Small Business
                      Administration under Section 301(c) or (d) of the Small
                      Business Investment Act of 1958; or (v) an employee
                      benefit plan within the meaning of Title I of the Employee
                      Retirement Income Security Act of 1974, if the investment
                      decision is made by a plan fiduciary, as defined in
                      Section 3(21) of such Act, which such plan fiduciary is
                      either a bank, insurance company, or registered investment
                      adviser, or if the employee benefit plan has total assets
                      in excess of $5,000,000; or

            (v)       The equity owner is a private business development company
                      as defined in Section 202(a)(22) of the Investment
                      Advisers Act of 1940.

      (b)______       The investor certifies that it is either (a) a bank as
                      defined in Section 3(a)(2) of the Act whether acting in
                      its individual or fiduciary capacity; (b) an insurance
                      company as defined in Section 2(13) of the Act; (c) an
                      investment company registered under the Investment Company
                      Act of 1940 or a business development company as defined
                      in Section 2(a)(48) of such Act; (d) a Small Business
                      Investment Company licensed by the U.S. Small Business
                      Administration under Section 301 (c) or (d) of the Small
                      Business Investment Act of 1958; or (e) an employee
                      benefit plan within the meaning of Title I of the Employee
                      Retirement Income Security Act of 1974, if the investment
                      decision is made by a plan fiduciary, as defined in
                      Section 3(21) of such Act, and the plan fiduciary is
                      either a bank, insurance company or registered investment
                      adviser, or if the employee benefit plan has total assets
                      in excess of $5,000,000.
----------

      (3)   An investor initialing this paragraph must provide a questionnaire
            from each of its equity owners. If the investor is a trust, only a
            trust which is revocable and which may be amended at the sole
            discretion of its grantor is eligible to qualify as an accredited
            investor under this item 6(a). The grantors of the trust are deemed
            to be the equity owners of the trust and each grantor must provide a
            questionnaire.

                                       12
<PAGE>

      (c)______       The investor certifies that it is a private business
                      development company as defined in Section 202(a)(22) of
                      the Investment Advisers Act of 1940.

      (d)______       The investor certifies that the investor is an
                      organization described in Section 501(c)(3) of the
                      Internal Revenue Code of 1986, as amended, not formed for
                      the specific purpose of acquiring Securities with total
                      assets exceeding $5,000,000.

      (e)______       The investor certifies that the investor is a corporation,
                      Massachusetts or similar business trust or partnership,
                      not formed for the specific purpose of acquiring
                      Securities with total assets exceeding $5,000,000.

      (f)______       The investor certifies that the investor is a trust, not
                      formed for the specific purpose of acquiring Securities,
                      with total assets exceeding $5,000,000 and whose purchase
                      is directed by a "sophisticated person", as defined in
                      Rule 506(b)(2)(ii) of Regulation D.

The undersigned certifies that the foregoing responses are true, complete and
accurate to the best of the undersigned's knowledge and belief. The undersigned
will provide such further information as may be requested by the Company to
verify this response. The undersigned will notify the Company in writing
regarding any material change to this response prior to the closing of the
purchase of the Securities. Absent such notification, the issuance of Securities
in the name of the undersigned shall be deemed to be an automatic affirmation by
the undersigned of the truth and accuracy of the statements and information set
forth above.

________________        ________________________________________________
Date                       Type or Print Name of Prospective Investor

                        ________________________________________________
                              Signature of Prospective Investor

                                      4-BExhibit 10.2

                      Amendment to Asset Purchase Agreement

     WHEREAS, MIRANDA III MINING (GUYANA) INC. a corporation incorporated under
the Companies Act of Guyana (hereinafter referred to as "Seller" or "Miranda
III") with an address at 93 Oronoque, Queenstown, Georgetown, Guyana, and VISTA
CONTINENTAL CORPORATION, a corporation formed under the laws of the State of
Delaware (herein after referred to as "Purchaser" or "Vista") with an address at
6600 West Charleston Blvd, Suite 118, Las Vegas, Nevada 89146., entered into an
asset purchase agreement (the "Agreement") on June 30th, 2004 for the purchase
of a 40% interest in the ownership of MIRANDA I MINING (GUYANA) INC., a
corporation incorporated under the Companies Act of Guyana (hereinafter referred
to as "Miranda I").

     WHEREAS, the Agreement was expected to close on or before July 30, 2004,
subject to the satisfactory completion of a due diligence review of the assets
and liabilities of Miranda I, Miranda III, and Vista.

     WHEREAS, both parties wish to extend the time of the closing of the
Agreement in order to complete their due diligence review.

     WHEREAS, the parties have mutually agreed to amend and modify the
agreement;

     NOW, THEREFORE, the parties, for mutually accepted and agreed upon
consideration, hereby amend and modify the Agreement as follows:

1. Section 8.1 of the Agreement shall now read as follows:

Section 8.1 Closing Date. The closing and consummation of the transactions
contemplated by the Agreement (the "Closing") shall take place at a location to
be mutually agreed upon by the parties on or before August 20, 2004 (the
"Closing Date"). All proceedings to take place on the Closing Date shall be
deemed to take place simultaneously and no delivery shall be deemed to have been
made until all such proceedings have been completed.

<PAGE>

2. Expect as here specifically modified and amended, all other terms and
conditions of the Agreement are hereby confirmed.

     WITNESS WHEREOF, the parties have executed this Agreement as of the date
and year written below.

                                       VISTA CONTINENTAL CORPORATION

                                       By: ____________________________
                                           Dr. Lawrence Nash
                                           Title: President
                                           Dated: 7/28/04

                                       MIRANDA III MINING (GUYANA) INC.

                                       By: ____________________________
                                           Alberto DoCouto
                                           Title: President
                                           Dated: 7/28/04

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]